Drug profile · INN
netarsudil mesylate
RHOPRESSA
netarsudil mesylate (RHOPRESSA) is a rho-associated protein kinase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — netarsudil mesylate
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
netarsudil mesylate (RHOPRESSA) is a rho-associated protein kinase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Rho-associated protein kinase inhibitor
Primary target: Rho-associated protein kinase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is netarsudil mesylate?
netarsudil mesylate (RHOPRESSA) is a rho-associated protein kinase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for netarsudil mesylate?
RHOPRESSA is a marketed brand name for netarsudil mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of netarsudil mesylate?
netarsudil mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.